REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Seer's management is scheduled to participate in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time / 1:05 p.m. Pacific Time. A live webcast of the session will be available on ...

Core Insights - Seer, Inc. is participating in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA, highlighting its position in the life sciences sector [1] - The management will engage in a fireside chat on August 14th, 2024, providing an opportunity for investors to gain insights into the company's developments [2] Company Overview - Seer is a life sciences company focused on developing transformative products for proteomics, specifically through its Proteograph Product Suite [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software for deep proteomic analysis, designed to be efficient and user-friendly [3] - The product suite is intended for research use only and is not meant for diagnostic procedures [3]

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $3.1 million, a decrease of 23% compared to $4 million in Q2 2023, primarily due to a decrease in related party and grant revenue [22][24] - Gross profit was $1.7 million for Q2 2024, representing a gross margin of 56%, compared to $2.3 million and a gross margin of 57% in Q2 2023 [24] - Net loss for Q2 2024 was $22.9 million, compared to $23.4 million in Q2 2023 [26] Business Line Data and Key Metrics Changes - Product revenue for Q2 2024 was $2.2 million, including $420,000 from related party revenue, consisting of sales of SP-100 instruments and consumable kits [22] - Service revenue was $845,000 in Q2 2024, including $163,000 from related party revenue, primarily related to STAC service projects [23] - Grant and other revenue was $46,000 for Q2 2024, consisting of lease and shipping revenue [24] Market Data and Key Metrics Changes - The company experienced elongated sales cycles due to constrained capital budgets around instrumentation, impacting the purchase of new instrumentation [23][30] - The company opened a STAC lab in Germany in June 2024 to enhance access for European researchers [7][34] Company Strategy and Development Direction - The company is focused on enhancing access to the Proteograph product suite and assisting customers in generating novel data while reducing operating cash burn [4][28] - The company aims to drive evidence and publications, enhance access to the Proteograph, innovate with products, and expand applications [21][28] - The launch of the 2024 Seer Insights grant program aimed to support innovative researchers, resulting in increased awareness and demand for the technology [8][9] Management's Comments on Operating Environment and Future Outlook - Management noted a challenging macro environment for the adoption of novel technology, leading to a slower recovery in the second half of the year than previously anticipated [26][27] - The revised revenue guidance for 2024 is now expected to be in the range of $13 million to $15 million, down from the previous guidance of $16 million to $18 million [27] Other Important Information - The company ended Q2 2024 with approximately $344.6 million in cash, cash equivalents, and investments [26] - The company has seen an increase in the number of publications showcasing the value of its technology, with 10 preprints and 11 peer-reviewed publications to date [10][12] Q&A Session Summary Question: Could you comment on the length of the sales cycle that you saw in the second quarter? - Management indicated that the sales cycle is being pushed out due to constrained capital budgets, reflecting a broader trend in the market [30] Question: What are the key underlying assumptions around the acceleration and the top line in 2H? - Management expressed confidence in the second half ramp due to a strong pipeline and increased interest from publications [32] Question: Could you provide some color around the traction generated by the STAC in Germany? - Management noted that the STAC in Germany became operational in June and is beginning to process customer samples, with expectations for revenue to follow similar lines as the U.S. STAC [34][36] Question: How have recent publications aided in conversations with customers? - Management highlighted that publications demonstrate the differentiated biological insights provided by the Proteograph, leading to increased customer interest and adoption [38][41] Question: Can you discuss the split between pharma and academic customers in your sales funnel? - Management noted a shift in the pipeline, with academic opportunities now comprising about 60% of the pipeline, reflecting increased interest from academic institutions [43]

Seer, Inc. (SEER) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.78%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.32, delivering a surprise of -3.23%. Over the last four quarters, the company has surpassed co ...

Core Insights - Seer, Inc. is set to report its financial results for Q2 2024 on August 8, 2024, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company specializes in proteomics and has developed the Proteograph Product Suite, which enables deep and unbiased proteomic analysis [3] Company Overview - Seer, Inc. is a life sciences company focused on creating transformative products that provide new access to the proteome [3] - The Proteograph Product Suite includes engineered nanoparticles, consumables, automation instrumentation, and software, designed for efficient and scalable proteomic analysis [3] - The Proteograph workflow is user-friendly and compatible with widely used laboratory instruments, making it suitable for various labs [3] - The products are intended for research use only and are not designed for diagnostic purposes [3]

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Se ...

Core Insights - Strategic Environmental & Energy Resources, Inc. (SEER) has received a purchase order worth approximately $600,000 from Biochar Now, LLC (BCN) for the provision of kilns as part of BCN's nationwide expansion program [1][6] - BCN, in collaboration with AgriCap Group, LLC, has launched an "Insured Carbon" program that offers fully insured biochar carbon credits, enhancing the reliability and marketability of its carbon credits in the global market [2][11] - SEER is actively pursuing the establishment of a joint venture facility in Texas with BCN to produce biochar and is exploring the processing of fiberglass waste and other composites at this facility [3][12] Company Overview - SEER specializes in identifying, securing, and commercializing patented environmental clean technologies across various sectors, including oil & gas, renewable fuels, and waste management [4] - The company operates through two wholly-owned subsidiaries and two majority-owned subsidiaries, focusing on minimizing hazardous waste streams and processing waste into renewable fuels [4] Strategic Partnerships and Growth - SEER's collaboration with BCN is aimed at developing cost-effective kiln manufacturing processes to enhance biochar production efficiency and minimize capital expenditures for new production sites [6][10] - BCN has established five operational locations and is developing additional biochar production sites across North America and Southeast Asia, indicating a strong growth trajectory [6] - SEER's involvement in the biochar market is expected to create multiple revenue streams, including kiln sales, product sales, and carbon credit sales, thereby increasing shareholder equity [12]

Core Insights - Seer, Inc. has highlighted the impact of spaceflight on human physiology through recent studies, showcasing its Proteograph technology's ability to uncover significant proteomic changes [5][6][10] Group 1: Seer's Technology and Products - Seer's Proteograph XT Assay Kit enables rapid and unbiased proteomics research, capable of detecting over 60,000 peptides and 8,000 proteins in human plasma studies [3][8] - The Proteograph Product Suite integrates engineered nanoparticles, consumables, and software for deep proteomic analysis, designed for efficiency and ease of use in various laboratory settings [8] - The technology has been utilized to identify 23,164 peptides mapping to 2,992 unique protein groups, demonstrating its capability in high-resolution proteomic profiling [7] Group 2: Research Findings - Studies from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with some protein alterations persisting six months post-mission [2][6] - The research indicates significant alterations in proteins related to coagulation, wound healing, antioxidation, and brain function, emphasizing the physiological impacts of spaceflight [2][6] - The findings contribute to a comprehensive atlas of molecular and physiological profiles from multiple space missions, providing valuable data for future aerospace research [10][11] Group 3: Collaboration and Future Directions - Collaboration between Seer and researchers has led to the identification of novel protein metrics, potentially paving the way for new therapeutic and biomarker discovery [11] - The studies aim to monitor physiological changes over time, which could inform the development of personalized countermeasures for astronauts [11]

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Omid Farokhzad, M.D., Chair & Chief Executive Officer of Seer said, "Exploring the effects of space flight on the human body presents an intriguing frontier for proteomic research. These papers highlight Seer's technology to provide unbiased insights into the proteome and shed light on dysfunctional biological alterations. At Seer, we empower researchers in detecting proteins and pept ...

REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date utilizing the Seer Proteograph™ Product Suite and Thermo Fisher Scientific's Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer. This pioneering research involved a multi-cancer case-control cohort of 2,840 su ...